DNL593
Phase 2Small molecule
DNL593 is one of 12 small molecule programs targeting Frontotemporal Dementia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Frontotemporal Dementia
#DrugCompanyPhaseTrials
1Celexa
AbbVieApproved
Namenda
AbbVieApproved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Glucophage
EMD SeronoApproved
Rayos
RRoxane Laboratories
Approved
Brintellix
TakedaPhase 2
Medrol
PfizerPhase 1
NS101
NNeuracle Science Co., LTD.
Phase 2
DNL593
DDenali Therapeutics Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DNL593. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDenali Therapeutics Inc.